Recent treatment innovations for lung cancer and melanoma have improved survival overall but also increased disparities in survival according to income, researchers found.

Researchers from the University of Birmingham's Bladder Cancer Research Center have used a new method to detect chemical ...

A novel drug-releasing system for bladder cancer that allows for sustained delivery of medicine for several weeks recently received FDA approval after producing superior and longer-lasting response ...

When treating patients with bladder cancer using gemcitabine intravesical system, regular AE monitoring is necessary, said ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC ...

Adding TAR-200 to neoadjuvant cetrelimab improved the pCR rate in patients with muscle-invasive bladder cancer in a phase 2 trial.

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United ...

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

The FDA has approved Inlexzo, a first-of-its-kind intravesical drug-delivery system for BCG-unresponsive non-muscle-invasive ...